WeVote
Log In

Bill

Bill

LC 1934

Generally revise laws relating to insurance coverage relating to cancer

2025 Regular Session

A draft law to broadly revise cancer insurance coverage, aiming to standardize and expand coverage for diagnostics, treatments, and related costs across plans.

(LC) Draft Ready for Delivery
#healthcareservices(seealso:health) #insurance
0
WeVote Research Nonpartisan
Bill Summary · LC 1934

LC 1934 — Generally revise laws relating to insurance coverage relating to cancer

Overview

LC 1934 is a draft bill introduced on November 23, 2024, with the stated aim of generally revising the laws governing insurance coverage for cancer-related care. The bill is classified as a health care services/insurance measure and is in the drafting and refinement phase.

Purpose and Intent

  • The title indicates a broad revision of existing insurance coverage laws as they pertain to cancer.
  • The forthcoming text is expected to standardize, expand, or clarify coverage requirements for cancer-related services, including diagnostics, treatments, medications, and potentially related supports.
  • At this stage, the exact substantive provisions are not released, so the specific standards, mandates, or protections remain to be seen in the final draft.

Scope and Provisions (Status is Draft)

  • The current public description confirms its focus on insurance coverage for cancer, but concrete provisions (e.g., mandated coverages, cost-sharing limits, prior authorization rules, timelines, or exclusions) are not yet published.
  • Potential areas typically addressed in cancer-coverage bills may include:
    • Coverage for approved cancer treatments and associated services (chemotherapy, radiation, surgery, immunotherapy, etc.).
    • Diagnostic testing and recommended screenings.
    • Coverage of genetic/genomic testing when clinically indicated.
    • Consumer protections such as limits on cost-sharing, exclusions, or delays in coverage.
    • Requirements related to prior authorization, network adequacy, and transparency.
    • Provisions related to clinical trials and access to innovative therapies.
  • Final provisions, thresholds, definitions (e.g., what constitutes “cancer care,” “reasonable and necessary” treatments), and any exemptions will be specified in the enacted text.

Who Would Be Affected

  • Individuals with cancer who hold insured health plans.
  • Other insureds under health insurance plans that cover cancer care.
  • Health insurers and health benefit plan administrators.
  • Health care providers and hospitals delivering cancer care.
  • Employers offering group health coverage may be affected indirectly through plan design changes.

Procedural Timeline and Status

  • Introduced: November 23, 2024.
  • Legislative Actions (selected):
    • 2024-11-23: Drafter Assigned
    • 2025-02-11 to 2025-02-18: Drafts moving through input/proofing, legal review, edit, and final drafting stages.
    • 2025-02-18: (LC) Draft in Final Drafter Review; Draft in Assembly; Draft Ready for Delivery
  • Status: Draft ready for delivery; currently in Assembly-drafting phase with finalization pending.

Potential Impact and Considerations

  • If enacted, could standardize or expand coverage for cancer care and reduce variability across plans.
  • Possible effects on premium costs, plan design, and out-of-pocket costs for patients.
  • Regulatory and enforcement implications for insurers and state health regulators.
  • Implementation timeline and transition provisions will be important for plan changes.

Next Steps / How to Track

  • Monitor for the final bill text, committee referrals, and any amendments.
  • Look for fiscal notes, cost impact analyses, and implementation dates once the final draft is released.
  • Track voting and potential regulatory guidance or required plan amendments following enactment.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.